Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott J Rodig

Showing results (211-220 of 293) with videos related to

Pageof 30
Sort By:
Cancer Research|July 28, 2011
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitorsTakaaki Sasaki, Jussi Koivunen, Atsuko Ogino, et al.
Blood|December 19, 2013
A targeted mutational landscape of angioimmunoblastic T-cell lymphomaOreofe Odejide, Oliver Weigert, Andrew A Lane, et al.
Cancer Immunology Research|October 18, 2017
Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal CancerYohei Masugi, Reiko Nishihara, Tsuyoshi Hamada, et al.
Nature Communications|December 31, 2024
Cancer-specific innate and adaptive immune rewiring drives resistance to PD-1 blockade in classic Hodgkin lymphomaJulia Paczkowska, Ming Tang, Kyle T Wright, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib StudyAlexander M Lesokhin, Stephen M Ansell, Philippe Armand, et al.
Cell Stem Cell|December 20, 2016
Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug ToleranceBrian B Liau, Cem Sievers, Laura K Donohue, et al.
Medrxiv : the Preprint Server for Health Sciences|November 14, 2023
A multidimensional analysis reveals distinct immune phenotypes and the composition of immune aggregates in pediatric acute myeloid leukemiaJoost B Koedijk, Inge van der Werf, Livius Penter, et al.
Cancer Immunology Research|September 30, 2024
A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal CancerBrandon M Huffman, Osama E Rahma, Kevin Tyan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 13, 2024
Next-Generation Sequencing-Based MSI Scoring Predicts Benefit in Mismatch Repair-Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1DJonathan D Schoenfeld, Nilofer S Azad, Jacob Gross, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 19, 2009
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemiaAkinori Yoda, Yuka Yoda, Sabina Chiaretti, et al.
Pageof 30

Showing results (211-220 of 293) with videos related to

Sort By:
Pageof 30
Cancer Research|July 28, 2011
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitorsTakaaki Sasaki, Jussi Koivunen, Atsuko Ogino, et al.
Blood|December 19, 2013
A targeted mutational landscape of angioimmunoblastic T-cell lymphomaOreofe Odejide, Oliver Weigert, Andrew A Lane, et al.
Cancer Immunology Research|October 18, 2017
Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal CancerYohei Masugi, Reiko Nishihara, Tsuyoshi Hamada, et al.
Nature Communications|December 31, 2024
Cancer-specific innate and adaptive immune rewiring drives resistance to PD-1 blockade in classic Hodgkin lymphomaJulia Paczkowska, Ming Tang, Kyle T Wright, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib StudyAlexander M Lesokhin, Stephen M Ansell, Philippe Armand, et al.
Cell Stem Cell|December 20, 2016
Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug ToleranceBrian B Liau, Cem Sievers, Laura K Donohue, et al.
Medrxiv : the Preprint Server for Health Sciences|November 14, 2023
A multidimensional analysis reveals distinct immune phenotypes and the composition of immune aggregates in pediatric acute myeloid leukemiaJoost B Koedijk, Inge van der Werf, Livius Penter, et al.
Cancer Immunology Research|September 30, 2024
A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal CancerBrandon M Huffman, Osama E Rahma, Kevin Tyan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 13, 2024
Next-Generation Sequencing-Based MSI Scoring Predicts Benefit in Mismatch Repair-Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1DJonathan D Schoenfeld, Nilofer S Azad, Jacob Gross, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 19, 2009
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemiaAkinori Yoda, Yuka Yoda, Sabina Chiaretti, et al.
Pageof 30